Intravitreal Ranibizumab Therapy Versus Intravitreal Conbercept Therapy For Idiopathic Choroidal Neovascularization:A Comparative Study On Visual Acuity And Central Macular Thickness

Objective: The comparison of the clinical safety and efficacy of intravitreal ranibizumab and intravitreal conbercept for subfoveal idiopathic choroidal neovascularization(ICNV).Methods: 42 eyes in 42 patients with subfoveal idiopathic choroidal neovascularization were treated in Department of Ophthalmology of the First Hospital of China Medical University from September 2015 to October 2017.26 eyes received intravitreal ranibizumab(0.5mg/0.05ml)and 16 eyes received intravitreal conbercept(0.5mg/0.05ml).Injection was repeated if optical coherence tomography showed subretinal fluid or intraretinal edema at a four week interval.Results: At the beginning of the ranibizumab group the Log MAR BCVA is 0.6±0.3,at the 6 months of follow-up the Log MAR BCVA improved to 0.3±0.2(P=0.003).In the conbercept group,the Log MAR BCVA improved from 0.5±0.2 at the beginning to0.3±0.1 at the 6 months of follow-up(P=0.014).The difference of the Log MAR BCVA between the two groups at final follow-up were not significant(P=0.594).In the ranibizumab group and the conbercept group CMT decreased significantly at the final-up.In the ranibizumab group,the CMT decreased from 371.1±101.0μm to 265.1±92.4μm(P=0.001).In the conbercept group,the CMT decreased from 333.9±88.6μm to214.4±54.4μm(P=0.001).There were no significant differences of CMT decreased between the ranibizumab group and conbercept group at the final-up(P=0.542).The average number of intravitreal injection was in 2.4±0.8 in ranibizumab group and 2.4±0.9in conbercept group.There were no systemic or ocular adverse events observed except for eight patients with subconjunctival hemorrhage in the ranibizumab group and five patients in conbercept group.Conclusions: Intravitreal ranibizumab injection and conbercept injection are both effective and safety for the patients with ICNV.Large long-term and controlled clinical trials are also necessary to assess the safety and efficacy of this treatment modality.